Cutting Edge: Low-dose Recombinant IL-2 Treatment Prevents Autoantibody Responses in Systemic Lupus Erythematosus via Regulatory T Cell-independent Depletion of T Follicular Helper Cells.
Santana S, Papillion A, Foote JB, Bachus H, León B, De Miguel C, Ballesteros-Tato A.
J Immunol. 2024 Oct 15;213(8):1053-1060. doi: 10.4049/jimmunol.2400264.
PMID:39195194
Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models.
Pillarisetti K, Yang D, Luistro L, Yao J, Smith M, Vulfson P, Testa JS, Ponticiello R, Brodeur S, Heidrich B, Packman K, Singh S, Attar R, Elsayed Y, Philippar U.
Blood. 2026 Feb 19;147(8):834-847. doi: 10.1182/blood.2025030027.
PMID:41100731
Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies.